The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...